Study to Assess Adverse Events and Change in Disease State of Oral Venetoclax in Combination With Subcutaneous (SC) Azacitidine in Newly Diagnosed Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Intensive Chemotherapy in China

NCT05144243 · clinicaltrials.gov ↗

PHASE4

Phase

ACTIVE_NOT_RECRUITING

Status

44

Enrollment

INDUSTRY

Sponsor class

Conditions

Acute Myeloid Leukemia (AML)

Interventions

DRUG: Venetoclax
DRUG: Azacitidine

Sponsor

AbbVie

Collaborators

[object Object]